泰達股份(000652.SZ):擬啟動公司債券第二期發行工作及追加增信措施
格隆匯 9 月 11日丨泰達股份(000652.SZ)公佈,公司於2020年3月25日成功發行了天津泰達股份有限公司2020年面向合格投資者公開發行公司債券(第一期)(疫情防控),發行規模3.56億元,票面利率7%。
近期,公司擬啟動公司債券第二期發行工作,為保證發行成功率,經與天津國康信用增進有限公司(“國康信用”)協商,由其為本期債券品種一的發行提供信用增進服務。公司向其支付信用增進服務費,增信費率為1.16%/年,並以三級子公司江蘇寶華文化發展有限公司(“寶華文化”)所持有的價值2.78億元(預評估價值)的寶華山門下項目商業街資產向其提供反擔保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.